Table 2.

Sensitivity, specificity, positive, and negative predictive value for CIN3+ and referral percentage among hrHPV-positive women of the CADM1-m18/MAL-m1 marker panel at different cutoffs, cytology, and cytology combined with HPV16/18 positivity

Triage markerSensitivity (in total 38 CIN3+)Specificity (in total 198 ≤CIN2)Positive predictive valueNegative predictive valueReferral%
CADM1-m18 combined with MAL-m1 for thresholds:
 specificity ≥20%100% (92.4–100)22.7% (20.2–25.2)19.9% (14.2–25.6)100% (99.0–100)80.9% (75.9–85.9)
 specificity ≥30%97.4% (86.2–99.9)32.3% (28.9–35.9)21.6% (15.4–27.8)98.5% (95.5–99.9)72.5% (66.8–78.2)
 specificity ≥40%86.8% (75.0–94.4)43.4% (39.2–47.8)22.8% (16.0–29.6)94.5% (89.8–99.2)61.4% (55.2–67.6)
 specificity ≥50%84.2% (72.0–92.7)52.5% (47.7–57.3)25.0% (17.5–32.5)94.4% (90.1–98.7)54.2% (47.8–60.6)
 specificity ≥60%81.6% (69.0–91.0)62.6% (57.5–67.5)29.5% (20.8–38.2)94.7% (90.9–98.5)44.5% (38.2–50.8)
 specificity ≥70%68.4% (50.0–81.1)75.3% (70.0–79.9)34.7% (23.9–45.5)92.5% (88.4–96.6)31.8% (26.9–37.7)
 specificity ≥80%60.5% (47.1–74.6)83.3% (78.4–87.4)41.8% (28.8–54.8)91.7% (87.7–95.7)23.3% (17.9–28.7)
Cytology65.8% (52.3–79.0)78.8% (73.7–83.1)37.3% (25.7–48.9)92.3% (88.3–96.3)28.4% (22.6–34.2)
Cytology combined with HPV16 and 18 genotyping84.2% (72.0–92.7)54.0% (49.2–58.7)26.0% (18.2–33.8)94.7% (90.6–98.8)52.1% (45.7–58.5)